Express News | Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Press Release: Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank analyst George Farmer maintains $Tempest Therapeutics(TPST.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 53.4%
Scotiabank Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Sector Update: Health Care Stocks Rise Late Afternoon
Top Midday Gainers
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Jumps as FDA Aligns With Trial Design for Cancer Drug
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Express News | Tempest Therapeutics Shares up 4.2% Premarket After Co Reports Positive FDA Feedback for Liver Cancer Drug Study
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding Uncertainties
Express News | Tempest Therapeutics Inc - Phase 3 Study Start Planned for Q1 2025
Express News | Tempest Therapeutics Inc: Overall Survival, Strongest Result From Phase 2 Trial, Will Be Primary Study Endpoint
Express News | Tempest Therapeutics Inc: Broad Agreement on Pivotal Phase 3 Study Plan, Including Use of Current Amezalpat Dose and Schedule
Express News | Tempest Announces Successful End-of-Phase 2 Meeting With FDA for Amezalpat (Tpst-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Announces Successful End-of-Phase 2 Meeting With FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma